2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baseline
1999
Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans
Fujita M, Woods S, Verhoeff N, Abi-Dargham A, Baldwin R, Zoghbi S, Soares J, Jatlow P, Krystal J, Rajeevan N, Charney D, Seibyl J, Innis R. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. European Journal Of Pharmacology 1999, 368: 161-172. PMID: 10193652, DOI: 10.1016/s0014-2999(99)00013-8.Peer-Reviewed Original ResearchConceptsClinical effectsReceptor levelsReceptor densityReceptor occupancyChronic benzodiazepine administrationBenzodiazepine receptor densityHealthy human subjectsComparison of baselineSingle photon emissionHopkins Verbal Learning TestInduced sedationVerbal Learning TestBenzodiazepine administrationOral administrationBaseline valuesBenzodiazepine receptorsTolerance developmentDay 3Day 17Day 4Day 10Central typeLearning TestReceptorsHuman subjects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply